Genmab — Februar 2023
-
When Pfizer buys Seagen, Pfizer will become owner of that 50% Tivdak share and Pfizer will take on all corresponding obligations. And Pfizer can then decide to get into discussions with Genmab to alter that relationship should they want to. But it is all early days, first see if that take-over materialises. And maybe Tivdak is the reason they want Seagen
-
Genmab leverer solidt regnskab, moderat skuffende forventninger https://ugebrev.dk/life-science/genmab-leverer-solidt-regnskab-moderat-skuffende-forventninger/
-
E L så forstår jeg det bedre, jeg mente, at du skrev at Pfifer ville lave deres egen portefølge og de måske ikke var interesseret i Tivak, jeg vil da også tro, at det ville være attraktivt af få fingre i det produkt, men selvfølgeligt er det alt for tidligt at gisne om et evt. salg af Seagen, så længe det kun er rygter.
-
-
-
Transactions in connection with share buy-back program https://www.proinvestor.com/investornyt/947259/transactions-in-connection-with-share-buy-back-program
-
Godmorgen
-
Tirsdagens aviser med Mærsk, Novo Nordisk og Genmab https://www.proinvestor.com/investornyt/947528/tirsdagens-aviser-med-maersk-novo-nordisk-og-genmab
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind